Adrenal Tutulumu Olan Hodgkin Lenfomalı Bir Olguda Florodeoksiglukoz Pozitron Emisyon Tomografi-Bilgisayarlı Tomografinin Tanısal Değeri

Year 2016, Volume: 14 Issue: 2, 100 - 103, 01.09.2016

Doğan Köse , Yavuz Köksal

https://doi.org/10.4274/jcp.96168

Abstract

Hodgkin lenfomada HL , modern tedavilerle başarının artması geç etkilerin önlenmesi için tedavi yoğunluğunu azaltacak yeni yöntem arayışlarını getirmiştir. HL’de nadir tutulan, adrenal bezlerdeki malign hücre infiltrasyonunun saptanmasında florodeoksiglukoz FDG pozitron emisyon tomografi-bilgisayarlı tomografinin PET-BT hassasiyet ve özgüllüğü yüksektir. Bir yıl önce pubik kıllanma ve meme büyümesi nedeniyle araştırılan 7,5 yaşındaki bir kız hasta, yeni başlayan ateş, halsizlik, kilo kaybı ve gece terlemesi yakınmalarıyla başvurdu. Muayenesinde; hepatosplenomegali, evre 2 pubarş ve evre 1 telarş saptanan hastanın FDG PET-BT’sinde; yaygın lenf nodu tutulumu, dalak ve sol sürrenal bezinde artmış aktivite görüldü. Hastaya biyopsiyle HL, klinik ve laboratuvar değerleriyle de prematür pubarş PP tanısı konuldu. Antineoplastik tedavi sonrası çekilen FDG PET-BT’si tamamen normalleşen, pubarş ve telarşı duran hastada, 12 yaşındayken normal puberte başladı ve hasta halen sorunsuz olarak takip edilmektedir. Bu yazıda PP ve HL tanısı alan ve FDG PET-BT’sinde adrenal bezde artmış aktivite saptanan bir çocuk olgu sunulmuştur

Keywords

Adrenal, çocuk, pozitron emisyon tomografi, Hodgkin, pubarş

Diagnostic Value of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Patient with Adrenal Involvement of Hodgkin Lymphoma

Abstract

Improved success with the modern management of Hodgkin lymphoma HL leaded new method searches to diminish treatment intensities in order to prevent late effects. Sensitivity and specificity of fluorodeoxyglucose FDG positron emission tomography-computed tomography PET-CT is advanced in the determination of malign cell infiltrations in adrenal glands in patients with HL which is a rare finding. A 7.5 year old female patient that was investigated due to pubic hairs and breast development one year ago presented, with complaints of recently developed fever, asthenia, weight loss and night sweating. In her examination, hepatosplenomegaly, phase 2 pubarche and phase 1 thelarche were detected; in FDG PET-CT, advanced lymph node involvement and increased activity in spleen and left adrenal gland were also detected. The patient was diagnosed with HL by biopsy and premature pubarche PP by the laboratory values. In the patient, FDG PET-CT that is recorded after the antineoplastic treatment was completely normalized; pubarche and thelarche were completely rested and, normal puberty started when she was 12 years old. The patient has been followed up currently without any problems. In this report, a pediatric HL case with PP and increased activity in left adrenal gland determined by FDG PET-CT, has been presented

Keywords

Adrenal, child, positron emission tomography, Hodgkin’s, pubarche

References

• 1. Arya LS, Dinand V. Current strategies in the treatment of childhood Hodgkins disease. Indian Pediatr 2005;42:1115-28.
• 2. Pates FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/ CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics 2010;30:269-91.
• 3. Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32-7.
• 4. Ozimek A, Diebold J, Linke R, Heyn J, Hallfeldt K, Mussack T. Bilateral primary adrenal non-Hodgkin’s lymphoma and primary adrenocortical carcinoma-review of the literature preoperative differentiation of adrenal tumors. Endocr J 2008;55:625-38.
• 5. Spyroglou A, Schneider HJ, Mussack T, Reincke M, won Werder K, Beuschlein F. Primary adrenal lymphoma: 3 case reports with different outcomes. Exp Clin Endocrinol Diabetes 2011;119:208-13.
• 6. No authors listed. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-1991. A 27-year-old woman with Hodgkin’s disease and an adrenal mass. N Engl J Med 1991;324:400-8.
• 7. Ouansafi I, Bell S, Jaffe ES. Adrenal Hodgkin lymphoma. Br J Haematol 2010;148:341.
• 8. Bourne AE, Bell SW, Wayment RO, Schwartz BF. Primary Hodgkin lymphoma of the adrenal gland: a unique case presentation. Can J Urol 2009;16:4694-6.
• 9. Akçay MN, Tekin SB, Akçay G. Addisonian crisis due to adrenal gland metastasis in Hodgkin’s disease. Int J Clin Pract 2003;57:840-1.
• 10. Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920-6.
• 11. Elaini AB, Shetty SK, Chapman VM, Sahani DV, Boland GW, Sweeney AT, et al. Improved detection and characterization of adrenal disease with PET-CT. Radiographics 2007;27:755-67.
• 12. Leite NP, Kased N, Hanna RF, Brown MA, Pereira JM, Cunha R, et al. Cross-sectional imaging of extranodal involvement in abdominopelvic lymphoproliferative malignancies. Radiographics 2007;27:1613-34.
• 13. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988;6:931-3.
• 14. Ömür Ö, Baran Y, Oral A, Ceylan Y. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Diagn Interv Radiol 2014;20:185-92.
• 15. Chong S, Lee KS, Kim HY, Kim YK, Kim BT, Chung MJ, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics 2006;26:1811-24.
• 16. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 2001;86:266-73.
• 17. Gallamini A. Positron emission tomography scanning: a new paradigm for the management of Hodgkin’s lymphoma. Haematologica 2010;95:1046-8.
• 18. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9.